Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy.

Charo LM, Burgoyne AM, Fanta PT, Patel H, Chmielecki J, Sicklick JK, McHale MT.

J Natl Compr Canc Netw. 2018 Mar;16(3):238-242. doi: 10.6004/jnccn.2017.7039.

PMID:
29523662
2.

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.

Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R.

Cancer. 2018 Mar 15;124(6):1288-1296. doi: 10.1002/cncr.31175. Epub 2017 Dec 6.

3.

The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA.

Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R.

Mol Cancer Ther. 2018 Jan;17(1):297-305. doi: 10.1158/1535-7163.MCT-17-0360. Epub 2017 Nov 13.

PMID:
29133621
4.

Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.

Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R.

Cancer Res. 2017 Nov 15;77(22):6313-6320. doi: 10.1158/0008-5472.CAN-17-1569. Epub 2017 Sep 22.

PMID:
28939679
5.

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.

Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R.

Cancer Res. 2017 Oct 1;77(19):5419-5427. doi: 10.1158/0008-5472.CAN-17-0885. Epub 2017 Aug 14.

PMID:
28807936
6.

The Call of "The Wild"-Type GIST: It's Time for Domestication.

Alkhuziem M, Burgoyne AM, Fanta PT, Tang CM, Sicklick JK.

J Natl Compr Canc Netw. 2017 May;15(5):551-554. No abstract available.

7.

Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis.

Fero KE, Coe TM, Fanta PT, Tang CM, Murphy JD, Sicklick JK.

JAMA Surg. 2017 May 1;152(5):443-451. doi: 10.1001/jamasurg.2016.5047.

8.

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.

Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK.

J Transl Med. 2016 Dec 14;14(1):339.

9.

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.

Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R.

Clin Cancer Res. 2016 Nov 15;22(22):5497-5505. doi: 10.1158/1078-0432.CCR-16-0318. Epub 2016 May 16.

10.

Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA.

Coe TM, Fero KE, Fanta PT, Mallory RJ, Tang CM, Murphy JD, Sicklick JK.

J Gastrointest Surg. 2016 Jun;20(6):1132-40. doi: 10.1007/s11605-016-3134-y. Epub 2016 Mar 29.

11.

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2016 Apr;15(4):743-52. doi: 10.1158/1535-7163.MCT-15-0795. Epub 2016 Feb 12.

12.

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R.

Cancer Metastasis Rev. 2016 Jun;35(2):263-75. doi: 10.1007/s10555-016-9602-8. Review.

13.

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R.

Oncotarget. 2016 Mar 1;7(9):9707-17. doi: 10.18632/oncotarget.7110.

14.

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.

Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R.

Oncotarget. 2015 Oct 20;6(32):32602-9. doi: 10.18632/oncotarget.5289.

15.

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer.

Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Cell Cycle. 2015;14(11):1730-7. doi: 10.1080/15384101.2015.1033596.

16.

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.

Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Mol Cancer Ther. 2015 Jun;14(6):1488-94. doi: 10.1158/1535-7163.MCT-14-1061. Epub 2015 Apr 7.

17.

Cyclin alterations in diverse cancers: Outcome and co-amplification network.

Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Oncotarget. 2015 Feb 20;6(5):3033-42.

18.

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R.

Oncologist. 2014 Jun;19(6):631-6. doi: 10.1634/theoncologist.2013-0405. Epub 2014 May 5.

19.

In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.

Fanta PT, Sicklick JK, Betz BL, Peterson MR.

J Clin Oncol. 2015 Mar 10;33(8):e41-4. doi: 10.1200/JCO.2013.50.0082. Epub 2014 Mar 17. No abstract available.

20.

Leptomeningeal Metastasis from Appendiceal Adenocarcinoma: Case Report and Literature Review.

Mahta A, Kim RY, Fanta PT, Lawson JD, Kesari S.

J Gastrointest Cancer. 2012 Sep;43 Suppl 1:108-10. doi: 10.1007/s12029-011-9312-y. Review. No abstract available.

PMID:
21826409
21.

Gastric cancer.

Lawson JD, Sicklick JK, Fanta PT.

Curr Probl Cancer. 2011 May-Jun;35(3):97-127. doi: 10.1016/j.currproblcancer.2011.03.001. No abstract available.

PMID:
21635986
22.

Schistosomiasis and signet ring cell carcinoma of the rectum.

Canepa M, Fanta PT, Weidner N, Peterson MR.

Ann Diagn Pathol. 2012 Oct;16(5):385-7. doi: 10.1016/j.anndiagpath.2010.12.008. Epub 2011 May 4.

PMID:
21546296
23.

Hairy cell leukemia.

Fanta PT, Saven A.

Cancer Treat Res. 2008;142:193-209. Review.

PMID:
18283787
24.

In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.

Monk BJ, Alberts DS, Burger RA, Fanta PT, Hallum AV 3rd, Hatch KD, Salmon SE.

Gynecol Oncol. 1998 Nov;71(2):308-12.

PMID:
9826477
25.

In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.

Alberts DS, Fanta PT, Running KL, Adair LP Jr, Garcia DJ, Liu-Stevens R, Salmon SE.

Cancer Chemother Pharmacol. 1997;39(6):493-7.

PMID:
9118460

Supplemental Content

Loading ...
Support Center